<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Exact Sciences Test Portfolio</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: linear-gradient(135deg, #e0f7fa 0%, #b2ebf2 100%);
            padding: 40px 20px;
            min-height: 100vh;
        }
        
        .container {
            max-width: 1600px;
            margin: 0 auto;
            background: white;
            border-radius: 12px;
            box-shadow: 0 8px 32px rgba(0, 0, 0, 0.1);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #00acc1 0%, #00838f 100%);
            color: white;
            padding: 30px;
            text-align: center;
        }
        
        .header h1 {
            font-size: 32px;
            margin-bottom: 10px;
            font-weight: 600;
        }
        
        .header p {
            font-size: 16px;
            opacity: 0.95;
        }
        
        .table-wrapper {
            overflow-x: auto;
            padding: 20px;
        }
        
        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 14px;
        }
        
        thead {
            background: linear-gradient(135deg, #4dd0e1 0%, #26c6da 100%);
            color: white;
        }
        
        th {
            padding: 16px 12px;
            text-align: left;
            font-weight: 600;
            font-size: 13px;
            letter-spacing: 0.5px;
            border-bottom: 3px solid #00acc1;
        }
        
        tbody tr {
            transition: all 0.2s ease;
        }
        
        tbody tr:nth-child(odd) {
            background-color: #e0f7fa;
        }
        
        tbody tr:nth-child(even) {
            background-color: #b2ebf2;
        }
        
        tbody tr:hover {
            background-color: #80deea;
            transform: scale(1.01);
            box-shadow: 0 4px 12px rgba(0, 172, 193, 0.2);
        }
        
        td {
            padding: 14px 12px;
            border-bottom: 1px solid #b2dfdb;
        }
        
        .fda-approved {
            background-color: #a5d6a7;
            color: #1b5e20;
            padding: 6px 12px;
            border-radius: 20px;
            font-weight: 600;
            font-size: 12px;
            display: inline-block;
        }
        
        .fda-ldt {
            background-color: #ffcc80;
            color: #e65100;
            padding: 6px 12px;
            border-radius: 20px;
            font-weight: 600;
            font-size: 12px;
            display: inline-block;
        }
        
        .fda-development {
            background-color: #ce93d8;
            color: #4a148c;
            padding: 6px 12px;
            border-radius: 20px;
            font-weight: 600;
            font-size: 12px;
            display: inline-block;
        }
        
        .coverage-yes {
            color: #2e7d32;
            font-weight: 600;
        }
        
        .coverage-no {
            color: #c62828;
            font-weight: 600;
        }
        
        .coverage-expanding {
            color: #f57c00;
            font-weight: 600;
        }
        
        .product-name {
            font-weight: 600;
            color: #00695c;
        }
        
        .revenue-high {
            background-color: #c8e6c9;
            padding: 4px 8px;
            border-radius: 4px;
            font-weight: 600;
        }
        
        .revenue-medium {
            background-color: #fff9c4;
            padding: 4px 8px;
            border-radius: 4px;
            font-weight: 600;
        }
        
        .revenue-low {
            background-color: #f0f4c3;
            padding: 4px 8px;
            border-radius: 4px;
        }
        
        .footer {
            background-color: #e0f2f1;
            padding: 25px;
            text-align: center;
            font-size: 13px;
            color: #00695c;
            border-top: 3px solid #80cbc4;
        }
        
        .legend {
            display: flex;
            justify-content: center;
            flex-wrap: wrap;
            gap: 20px;
            margin-bottom: 15px;
        }
        
        .legend-item {
            display: flex;
            align-items: center;
            gap: 8px;
        }
        
        .legend-box {
            width: 20px;
            height: 20px;
            border-radius: 4px;
        }
        
        @media (max-width: 1200px) {
            table {
                font-size: 12px;
            }
            
            th, td {
                padding: 10px 8px;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>Exact Sciences Complete Test Portfolio</h1>
            <p>Comprehensive Analysis: FDA Status, Revenue, Coverage & Biomarkers (2024-2025)</p>
        </div>
        
        <div class="table-wrapper">
            <table>
                <thead>
                    <tr>
                        <th>Test Name</th>
                        <th>FDA Status</th>
                        <th>2024 Revenue</th>
                        <th>Launch Date</th>
                        <th>Medicare Coverage</th>
                        <th>Medicaid Coverage</th>
                        <th>Private Insurance</th>
                        <th>Biomarker Type</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td class="product-name">Cologuard (Original)</td>
                        <td><span class="fda-approved">FDA APPROVED</span><br><small>PMA P130017 (Aug 2014)</small></td>
                        <td class="revenue-high">~$2.0B<br><small>4M+ tests</small></td>
                        <td>August 2014<br><small>Expanded to 45+ in May 2019</small></td>
                        <td class="coverage-yes">YES<br><small>NCD 210.3, $493 reimb.</small></td>
                        <td class="coverage-yes">YES<br><small>$0 cost sharing (CA)</small></td>
                        <td class="coverage-yes">Broadly Covered<br><small>96%+ patients $0 OOP</small></td>
                        <td><strong>DNA methylation</strong> (NDRG4, BMP3)<br><strong>DNA mutations</strong> (7 KRAS)<br><strong>Protein</strong> (Hemoglobin)<br><small>11 total biomarkers</small></td>
                    </tr>
                    <tr>
                        <td class="product-name">Cologuard Plus</td>
                        <td><span class="fda-approved">FDA APPROVED</span><br><small>PMA P230043 (Oct 2024)</small></td>
                        <td class="revenue-low">Minimal<br><small>Launched March 2025</small></td>
                        <td>March 2025<br><small>FDA approved Oct 2024</small></td>
                        <td class="coverage-yes">YES<br><small>CPT 0464U, $592 reimb.</small></td>
                        <td class="coverage-yes">YES<br><small>In-network (CA)</small></td>
                        <td class="coverage-expanding">Expanding<br><small>MA transitioning, parity by 2026</small></td>
                        <td><strong>DNA methylation</strong> (LASS4, LRRC4, PPP2R5C)<br><strong>Protein</strong> (Hemoglobin)<br><small>5 total biomarkers</small></td>
                    </tr>
                    <tr>
                        <td class="product-name">Oncotype DX Breast</td>
                        <td><span class="fda-ldt">LDT - NOT FDA APPROVED</span><br><small>CLIA/CAP certified</small></td>
                        <td class="revenue-high">~$600M+<br><small>~200K+ patients (est.)</small></td>
                        <td>2004<br><small>Acquired by EXAS 2019</small></td>
                        <td class="coverage-yes">YES<br><small>CPT 81519, $3,416 reimb.</small></td>
                        <td class="coverage-yes">YES<br><small>Available to Medicaid</small></td>
                        <td class="coverage-yes">Broadly Covered<br><small>All major insurers</small></td>
                        <td><strong>mRNA expression</strong> (21 genes)<br>16 cancer-related + 5 reference<br><small>Includes ER, PR, HER2, Ki-67</small></td>
                    </tr>
                    <tr>
                        <td class="product-name">Oncotype DX DCIS</td>
                        <td><span class="fda-ldt">LDT - NOT FDA APPROVED</span><br><small>CLIA/CAP certified</small></td>
                        <td class="revenue-medium">Included in Oncotype<br><small>Part of 230K patients</small></td>
                        <td>December 2011<br><small>Acquired by EXAS 2019</small></td>
                        <td class="coverage-yes">YES<br><small>Part of Oncotype coverage</small></td>
                        <td class="coverage-yes">YES<br><small>Available to Medicaid</small></td>
                        <td class="coverage-yes">Covered<br><small>Major insurers</small></td>
                        <td><strong>mRNA expression</strong> (12 genes)<br>7 cancer-related + 5 reference<br><small>Ki-67, AURKA, BIRC5, etc.</small></td>
                    </tr>
                    <tr>
                        <td class="product-name">Oncotype DX Colon</td>
                        <td><span class="fda-ldt">LDT - NOT FDA APPROVED</span><br><small>CLIA/CAP, PLA 81525</small></td>
                        <td class="revenue-medium">Included in Oncotype<br><small>Part of 230K patients</small></td>
                        <td>January 2010<br><small>Acquired by EXAS 2019</small></td>
                        <td class="coverage-yes">YES<br><small>Part of Oncotype coverage</small></td>
                        <td class="coverage-yes">YES<br><small>Available to Medicaid</small></td>
                        <td class="coverage-yes">Covered<br><small>Major insurers</small></td>
                        <td><strong>mRNA expression</strong> (12 genes)<br>7 cancer-related + 5 reference<br><small>Stromal, cell cycle genes</small></td>
                    </tr>
                    <tr>
                        <td class="product-name">OncoExTra</td>
                        <td><span class="fda-ldt">LDT - NOT FDA APPROVED</span><br><small>CLIA/CAP certified</small></td>
                        <td class="revenue-low">~$30-40M<br><small>~5% of Precision Oncology</small></td>
                        <td>February 2023<br><small>Launched Feb 7, 2023</small></td>
                        <td class="coverage-yes">YES<br><small>NCD 90.2, NGS codes</small></td>
                        <td class="coverage-yes">Available<br><small>Follows Medicare</small></td>
                        <td class="coverage-yes">Broadly Covered<br><small>150M+ lives, 98% $0 OOP</small></td>
                        <td><strong>DNA sequencing</strong> (WES ~20K genes)<br><strong>RNA sequencing</strong> (Whole transcriptome)<br><small>Mutations, CNVs, fusions, TMB</small></td>
                    </tr>
                    <tr>
                        <td class="product-name">Oncodetect MRD</td>
                        <td><span class="fda-ldt">LDT - NOT FDA APPROVED</span><br><small>CLIA/CAP certified</small></td>
                        <td class="revenue-low">N/A<br><small>Launched April 2025</small></td>
                        <td>April 2025<br><small>Medicare coverage July 2025</small></td>
                        <td class="coverage-yes">YES<br><small>MolDX LCDs (CRC only)</small></td>
                        <td class="coverage-yes">Likely YES<br><small>Follows Medicare</small></td>
                        <td class="coverage-expanding">Expanding<br><small>Major insurers adding coverage</small></td>
                        <td><strong>ctDNA</strong> (Tumor-informed)<br>Tracks up to 200 patient variants<br><small>1 in 20,000 cfDNA sensitivity</small></td>
                    </tr>
                    <tr>
                        <td class="product-name">Cancerguard MCED</td>
                        <td><span class="fda-ldt">LDT - NOT FDA APPROVED</span><br><small>FDA IDE for FALCON study</small></td>
                        <td class="revenue-low">N/A<br><small>Launched Sept 2025</small></td>
                        <td>September 10, 2025<br><small>$689 self-pay</small></td>
                        <td class="coverage-no">NO<br><small>Investigational status</small></td>
                        <td class="coverage-no">NO<br><small>Not covered</small></td>
                        <td class="coverage-no">NO<br><small>Investigational by most insurers</small></td>
                        <td><strong>ctDNA methylation</strong><br><strong>Protein biomarkers</strong> (9 proteins)<br><small>CA-125, CEA, CA19-9, PSA, etc.</small></td>
                    </tr>
                    <tr>
                        <td class="product-name">Riskguard</td>
                        <td><span class="fda-ldt">LDT - NOT FDA APPROVED</span><br><small>CLIA/CAP certified</small></td>
                        <td class="revenue-low">Part of Screening<br><small>Included in $2.1B segment</small></td>
                        <td>February-March 2024<br><small>Launched Feb 28, 2024</small></td>
                        <td class="coverage-yes">YES<br><small>NCD 90.2/LCD L38972</small></td>
                        <td class="coverage-yes">YES<br><small>TAR may be required</small></td>
                        <td class="coverage-yes">Covered<br><small>UHC, Anthem, Cigna, Humana</small></td>
                        <td><strong>Germline DNA sequencing</strong><br>59 hereditary cancer genes<br><small>10+ cancer types assessed</small></td>
                    </tr>
                    <tr>
                        <td class="product-name">PreventionGenetics Portfolio</td>
                        <td><span class="fda-ldt">LDT - NOT FDA APPROVED</span><br><small>5,000+ distinct tests</small></td>
                        <td class="revenue-medium">~$100M<br><small>~5% of Screening segment</small></td>
                        <td>Acquired Dec 2021<br><small>Founded 2004</small></td>
                        <td class="coverage-yes">YES<br><small>Varies by test</small></td>
                        <td class="coverage-yes">YES<br><small>Varies by test, TAR required</small></td>
                        <td class="coverage-yes">Covered<br><small>Varies by test and insurer</small></td>
                        <td><strong>Germline DNA/RNA</strong><br>WES (PGxome), WGS (PGnome)<br><small>Custom gene panels available</small></td>
                    </tr>
                    <tr style="background-color: #f3e5f5;">
                        <td class="product-name">Oncoguard Liver (HCC)</td>
                        <td><span class="fda-development">IN DEVELOPMENT</span><br><small>Breakthrough Device (2019)</small></td>
                        <td class="revenue-low">N/A<br><small>Early access only</small></td>
                        <td>In Development<br><small>Launch timing TBD</small></td>
                        <td class="coverage-no">N/A<br><small>Not launched commercially</small></td>
                        <td class="coverage-no">N/A<br><small>Not launched commercially</small></td>
                        <td class="coverage-no">N/A<br><small>Not launched commercially</small></td>
                        <td><strong>cfDNA methylation</strong><br><strong>Protein</strong> (AFP)<br><small>88% CRC sensitivity reported</small></td>
                    </tr>
                    <tr style="background-color: #f3e5f5;">
                        <td class="product-name">Blood-based CRC Screening</td>
                        <td><span class="fda-development">IN DEVELOPMENT</span><br><small>PMA submission expected H1 2025</small></td>
                        <td class="revenue-low">N/A<br><small>Not launched</small></td>
                        <td>In Development<br><small>BLUE-C study ongoing</small></td>
                        <td class="coverage-no">N/A<br><small>Not launched commercially</small></td>
                        <td class="coverage-no">N/A<br><small>Not launched commercially</small></td>
                        <td class="coverage-no">N/A<br><small>Not launched commercially</small></td>
                        <td><strong>cfDNA methylation</strong><br>AI-based multiomics<br><small>88.3% CRC sensitivity (internal)</small></td>
                    </tr>
                    <tr style="background-color: #f3e5f5;">
                        <td class="product-name">Freenome Blood CRC Test</td>
                        <td><span class="fda-development">IN DEVELOPMENT</span><br><small>PMA submitted, pending approval</small></td>
                        <td class="revenue-low">N/A<br><small>Licensed Aug 2025</small></td>
                        <td>Expected 2026<br><small>Licensed from Freenome</small></td>
                        <td class="coverage-no">N/A<br><small>Pending FDA approval</small></td>
                        <td class="coverage-no">N/A<br><small>Pending FDA approval</small></td>
                        <td class="coverage-no">N/A<br><small>Pending FDA approval</small></td>
                        <td><strong>ctDNA methylation</strong><br>Multiomics platform<br><small>81.1% CRC sensitivity (PREEMPT)</small></td>
                    </tr>
                </tbody>
            </table>
        </div>
        
        <div class="footer">
            <div class="legend">
                <div class="legend-item">
                    <div class="legend-box" style="background-color: #a5d6a7;"></div>
                    <span>FDA Approved</span>
                </div>
                <div class="legend-item">
                    <div class="legend-box" style="background-color: #ffcc80;"></div>
                    <span>LDT (Not FDA Approved)</span>
                </div>
                <div class="legend-item">
                    <div class="legend-box" style="background-color: #ce93d8;"></div>
                    <span>In Development</span>
                </div>
            </div>
            <p><strong>Source:</strong> Exact Sciences 2024 10-K, Earnings Calls, FDA PMA Database, Coverage Policies | <strong>Data as of:</strong> October 2025</p>
            <p style="margin-top: 10px;"><strong>Key Findings:</strong> 2 FDA-approved products generating ~$2.0B (73% of total revenue) | 7 commercial LDTs generating ~$755M (27%) | Total 2024 revenue: $2.758B from 4.6M tests</p>
        </div>
    </div>
</body>
</html>